The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC).
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Yuriko Takeda
No Relationships to Disclose
 
Toshihiro Misumi
No Relationships to Disclose
 
Motoko Suzuki
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst); OBI Pharma
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
 
Robert J. Mayer
Consulting or Advisory Role - Eisai
 
Jin Li
No Relationships to Disclose
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Merck Serono; Pierre Fabre; Roche/Genentech; Sanofi; Seagen; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Aptitude Health; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; Gilead Sciences; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Nordic Bioscience; Pierre Fabre; Seagen; SERVIER; Takeda/Lundbeck; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation; Gercor
 
Qian Shi
Honoraria - Chugai Pharma
Consulting or Advisory Role - Hoosier Cancer Research Network; Kronos Bio; Mirati Therapeutics; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Aimery De Gramont
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)